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Purpose: With the increasing number of active compounds avail-
able for advanced non-small cell lung cancer, it is useful to evaluate
whether surrogate end points can replace survival in randomized
trials for the rapid and efficient assessment of efficacy. We examined
the association between differences in overall survival and time to
progression (TTP) using a literature survey.
Methods: We used median TTP (MTTP) and median survival time
(MST) from 54 phase III trials of first-line chemotherapy involving
23,457 advanced non-small cell lung cancer patients in a multiple
linear regression analysis. The MST ratio in each trial was defined
as the ratio of MST in the investigational arm to that in the reference
arm. The MTTP ratio was defined similarly.
Results: The degree of the association between the MST and MTTP
ratios was only moderate both in the overall cohort (R2  0.33) and
various trial settings (R2  0.16–0.51), although the MTTP ratio
was an independent factor influencing the MST ratio in the multiple
regression model (p  0.01). This means that the MTTP ratio could
account for less than half of the variance in the MST ratio.
Conclusions: The TTP potentially acts as a surrogate marker, but
may not be still a definitive alternative in the first-line setting.
Key Words: Non-small cell lung cancer, Overall survival, Surro-
gate marker, Time to progression.
(J Thorac Oncol. 2009;4: 311–317)
Lung cancer is a leading cause of cancer deaths, andnon-small cell lung cancer (NSCLC) accounts for approx-
imately 75% of all lung cancer cases.1 The majority of
patients with NSCLC have inoperable locally advanced or
metastatic disease at the time of diagnosis. The standard
treatment for advanced NSCLC is platinum-based chemo-
therapy.2–4 The outcome is unsatisfactory, however, with a
median survival time (MST) of only approximately 1 year,
indicating the need for the development of novel anticancer
agents.
In developing new agents, the most important issue is
whether they prolong survival. This is usually evaluated in
phase III trials in which the primary end point is traditionally
overall survival (OS). However, patient death can be ob-
served only after prolonged follow-up, even in the treatment
of advanced NSCLC, despite a modest and slow survival
improvement over the years.5 In addition, with the increasing
number of active compounds available for the treatment of this
disease,6,7 any effect of first-line therapies on OS might poten-
tially be confounded by the effects of subsequent therapies.
Thus, it is of interest to investigate whether other
clinical end points could replace OS as the primary end point
in randomized trials for the treatment of patients with ad-
vanced NSCLC for the rapid and efficient assessment of the
efficacy of new agents. Time to progression (TTP) and
progression-free survival (PFS) have been proposed as ac-
ceptable endpoints for cancer clinical trials. Like survival,
they include all patients in the primary efficacy analysis and
have the advantage of achieving the trial end point sooner.8
They are not influenced by crossover effects or the use of
second-line therapies, despite the requirement for strict defini-
tions of disease progression, progression date, and follow-up
interval during the study period between the study arms.8
It was recently proposed that for a surrogate to be
appropriate, the effect of treatment on the surrogate end point
must predict that on the true end point, or a test of a statistical
hypothesis based on the surrogate end point should come to
the same conclusion as that obtained by a test based on the
primary end point.9 Assessments of surrogate markers have
been conducted for several cancers, including colon and
breast cancer, and some suggest strong correlations between
the parameters.10–12
This issue has not yet been fully addressed in the
treatment of advanced NSCLC.13 In addition, it is of interest
to know what factors the association between the OS and TTP
differences would be affected by, for generating relevant
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hypotheses in future studies. In this study, we assessed
whether any trial characteristics could affect the association
between the difference in OS and that in TTP, as well as
simply evaluating the overall association between the param-
eters, to discuss in which situations TTP would be used as a
surrogate marker for OS in advanced NSCLC.
METHODS
Search for Trials
We conducted a literature search for trials reported
between January 1994 and May 2006. To avoid publication
bias, both published and unpublished trials were identified
through a computer-based search of the PubMed database and
abstracts from the past 10 conferences of the American
Society of Clinical Oncology. We used the following search
terms: “lung neoplasm,” “carcinoma,” “nonsmall cell,” “che-
motherapy,” and “randomized controlled trial.” The search
was also guided by a thorough examination of reference lists
of original and review articles, relevant books, and the Phy-
sician Data Query registry of clinical trials.
Selection of Trials
Phase III trials were eligible if they compared first-line
systemic chemotherapy for advanced or metastatic NSCLC
with cytotoxic or molecular-targeted agents. We included
trials that provided data for both TTP and OS, whether their
definitions were documented or not. Trials were excluded if
they investigated only immunotherapy regimens or hormonal
therapies. Trials that were designed to assess combined mo-
dality treatments, including radiotherapy and surgery, were
also excluded.
Data Abstraction
To avoid bias in the data abstraction process, two
observers (K.H., Y.F.) independently abstracted the data from
the trials and subsequently compared their results. The fol-
lowing information was obtained from each report: year of
trial initiation (year when the first patient entered), number of
patients enrolled and randomized, proportion with poor per-
formance status (two or worse, defined primarily by the
Eastern Cooperative Oncology Group or World Health Or-
ganization criteria), gender, chemotherapy regimen, MST,
and median TTP (MTTP) pertreatment arm. Docetaxel, pac-
litaxel, vinorelbine, gemcitabine, and irinotecan were def-
ined as newer chemotherapeutic agents.14 Consequently, old
agents were defined as those that were developed before the
aforementioned drugs had been introduced clinically. All data
were checked for internal consistency, and disagreements
were resolved by discussions among the investigators, al-
though we did not formally record their frequencies and
patterns. For trials with more than two treatment arms, we
constructed multiple pairs of each investigational arm and the
reference arm.
Quantitative Data Synthesis
To investigate the association between the difference in
MST and in MTTP, we defined the MST ratio as the ratio of
MST in the investigation arm to MST in the reference arm
and the MTTP ratio as the ratio of MTTP in the investigation
arm to MTTP in the reference arm, (all measures in months).
Information from the phase III trials was evaluated using a
multiple linear regression model to determine whether the
following factors independently affected the MST ratio:
MTTP ratio; year of trial initiation; use of cisplatin, carbo-
platin, and old agents; number of agents combined (combi-
nation therapy versus single agent therapy); number of
randomized patients; and proportion of male patients. All
analyses were weighted by trial size. Regarding the “noneva-
luable” patients, we did not have enough information about
how they were handled in each trial; thus, the survival data
that we abstracted from each report were simply used for the
construction of the ratios, irrespective of how nonevaluable
patients were treated. The strength of associations was de-
fined a priori using the commonly accepted criteria for the
proportion of variation (R2) as 0–0.29  little or no associ-
ation, 0.30–0.69  moderate or weak association, and 0.70–
1.00  strong association.15
RESULTS
Trials Included in the Analysis
Of the 1255 trials screened, 54 trials involving 23,457
advanced NSCLC patients were identified as having data
regarding OS and TTP (Figure 1). Of the patients enrolled,
23,157 were randomly allocated to 121 chemotherapy arms.
Of these 54 trials, 11 had multiple arms: 9 of these had 3 arms
and 2 had 4 arms; thus, there were 67 trial pairs of the
investigational arm versus the reference arm (Table 1). Of
these trials, most had low proportions of female patients and
patients with poor performance status and most were pub-
lished as full-text papers. Regarding chemotherapy regimens
(Table 1), platinum-based chemotherapy was most frequently
investigated in phase III trials, as previously reported.5,16
Molecular-targeted agents were assessed in only nine regi-
mens, all in combination with cytotoxic chemotherapeutic
agents.
Definitions of TTP and OS in Each Trial
Of the 54 trials providing TTP data, 24 (44%) did not
describe its definition in the text and 7 were in abstract form
only. In the remaining 30 trials (56%), TTP was defined in the
text. In contrast, the definition of OS was documented in 35
trials (65%).
Association between the MST and MTTP Ratio
in the First-Line Chemotherapy Setting in the
Overall Cohort
We plotted the MTTP and MST ratios from all 67 trials
(Figure 2). There was a moderate relationship between the TTP
and OS differences, with a higher MTTP ratio correlated with a
higher MST ratio (univariate analysis, R2  0.33; p  0.01).
We conducted a multiple linear regression analysis for
the MST ratio using several trial characteristics as indepen-
dent variables, including the MTTP ratio for all 67 trials
(Table 2). Of these covariates, the MTTP ratio was an
independent factor influencing the MST ratio (p  0.01),
while none of the other factors predicted survival differences.
Hotta et al. Journal of Thoracic Oncology • Volume 4, Number 3, March 2009
Copyright © 2009 by the International Association for the Study of Lung Cancer312
This analysis defined the following formula to approximate
how a given MTTP ratio and other covariates likely affect the
MST ratio:
MST ratio 0.32 (MTTP ratio) 0.01 (“1” if the
year of trial initiation is 1998 or after)  0.04  (“1” if old
agents are not investigated)  0.04  (“1” if cisplatin is
investigated)  0.01  (“1” if carboplatin is investigated) 
0.16 (“1” if agents are combined) 0.01 (the proportion
of male patients)  0.51.
The regression coefficient of the MTTP ratio to the
MST ratio of 0.32 was clearly the highest of the covariates
(independent variables) used in this formula. These sug-
gest that the MST ratio was significantly and primarily
explained by the MTTP ratio, rather than the other covari-
ates.
Contrary, in this fitted formula, these trial characteris-
tics accounted for 41% of the variance in the MST ratio,
totally indicating a moderate probability of accurately pre-
dicting the MST ratio using this formula.
Association between the MST and MTTP Ratio
in the First-Line Chemotherapy Setting in
Several Subgroups
To investigate whether any of trial settings could affect
the relationship between the MST and MTTP ratios, eligible
trial pairs were subdivided into several subgroups (Table 3).
We found only moderate relationships between the 2 param-
eters in all the trial settings with the R2of 0.16 to 0.51,
indicating that the MTTP ratio could explain one sixth to half
of the variance in the MST ratio. In addition, none of the
assessed characteristics seemed to affect the association.
DISCUSSION
We found in this study that the MTTP ratio indepen-
dently affected the MST ratio in the multiple linear regression
analysis for the 67 trial pairs using several trial characteristics
as independent variables (Table 2). In this model, the regres-
sion coefficient of the MTTP ratio was high compared with
that of other covariates. In contrast, the degree of the asso-
ciation between the MST and MTTP ratios was moderate in
the overall cohort and various trial settings (Table 3).
In their abstracted database study, Johnson et al.13
investigated the role of TTP as a surrogate marker in the
treatment of advanced NSCLC by comparing incremental
differences in MST between the arms with those in MTTP.
They found a weak correlation (R2  0.19) between the
parameters. Here, we initially defined investigational and
reference arms in each eligible trial and then compared the
MST ratio with the MTTP ratio. In this setting, we found a
closer relationship (R2  0.33; Figure 2), mainly because we
used different parameters. The TTP potentially acts as a
surrogate marker, based on our following findings; (i) the
MTTP ratio was an independent factor influencing the MST
ratio in the multiple linear regression analysis and (ii) the
regression coefficient of the MTTP ratio to the MST ratio of
0.32 was clearly the highest of the covariates (independent
variables) used in this formula (Table 2). However, the
strength of the association seemed insufficient for the appli-
cation of this surrogate marker in daily practice because the
MST ratio could be predicted accurately by this factor in less
than half of the trials at most both in the overall cohort
(Figure 2.) and various subgroups (Table 3). Other investi-
gators also demonstrated that a reduction of at least 30% in
the risk of progression (or death) is needed for predicting a
FIGURE 1. Flow chart showing
the progress of trials through the
review.
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significant OS effect, and concluded PFS may not be a useful
surrogate in advanced NSCLC.17 Thus, the role of surrogate
markers, including TTP, in first-line chemotherapy for ad-
vanced NSCLC should be evaluated extensively before their
practical use in phase III trials.
For a surrogate to be appropriate, another essential
point is to understand how poststudy therapies can confound
any effects of first-line therapies on OS. Discordant results
between OS and surrogate markers caused by the influence of
some subsequent treatments have been reported for other
cancers.18 In the treatment of advanced NSCLC, a rapidly
growing number of effective salvage therapies has become
increasingly available such as docetaxel, pemetrexed, ge-
fitinib, and erlotinib.6,7 Indeed, they have been shown to yield
significant survival advantages even in a salvage setting.19–22
On the basis of this background, it might be reasonable that
the correlation between TTP and survival should weaken with
more effective salvage strategies available in our study.
However, this seems unlikely in our setting because the
majority of trials that were included were completed before
TABLE 1. Trial Demographics and Chemotherapy
Regimens in 67 Trial Pairs
Trial characteristics
Median no. of randomly assigned pts per trial
(range)
398 (72–1218)
Year of trial initiation (median; range) 1998 (1987–2002)
Publication type (full text/abstract form only) 51/16
Percentage of pts with poor PS (median, range)¶ 12 (0–100)
Percentage of female pts (median, range) 23 (4–59)
Percentage of stage IIIB pts (median, range) 33 (5–73)
Description of the definition for TTP (yes/no) 37/30
Description of the definition for OS (yes/no) 43/24
Description of the definition for both OS and
TTP (yes/no)
34/33
Description of the definition for sample size
(yes/no)
56/11




P  N vs. P  N 19
P  N vs. N 14
P  O vs. P  N 10
P  N vs. P  N  M 9
P  O vs. P  O 7
N vs. N 2
P  O vs. N 2
P vs. P  N 2
P  O vs. O 2
Docetaxel, paclitaxel, vinorelbine, gemcitabine, and irinotecan were defined as
newer chemotherapeutic agents.14 Drugs thought to act on known specific molecular
targets, e.g., tyrosine kinase inhibitors, neutralizing antibodies, matrix metalloproteinase
inhibitors, and antisense oligonucleotides, were defined as molecular-targeted agents.6
Old agents were defined as those that had been developed before the aforementioned
drugs were introduced clinically.
¶Poor PS (performance status) was defined as PS of two or worse.
pts, patients; P, platinum; N, new agents; O, old agents; M, molecular-targeted
agents.
FIGURE 2. Correlations between the MST (me-
dian survival time) ratio and MTTP (median time
to progression) ratio for all 67 trial pairs weighted
by number of randomized patients (R2  0.33).
The MST ratio in each trial was defined as the ra-
tio of MST in the investigational arm to MST in
the reference arm. The MTTP ratio was defined
similarly. Each trial is represented by a circle; the
size of each circle is proportional to the sample
size of randomized patients.
TABLE 2. Multiple Linear Regression Analysis for the MST






MTTP ratio 0.32 0.07 0.01
Year of trial initiation (1998
and after vs. 1997 and
before)
0.01 0.04 0.99










Difference in the proportion
of males between the arms
0.01 0.01 0.78
The MST (median survival time) ratio in each trial was defined as the ratio of MST
in the investigational arm to MST in the reference arm. The MTTP (median time to
progression) ratio in each trial was defined as the ratio of MTTP in the investigational
arm to MTTP in the reference arm. All analyses were weighted by trial size. R2: 0.41.
MTTP, median time to progression; MST, median survival time.
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such salvage therapy came to be commonly recognized and
because the effect of these agents on survival was significant
but, relatively, modest.23
In contrast, in designing recent clinical trials for first-
line chemotherapy in advanced NSCLC, surrogate markers,
including TTP or PFS other than the main end point, OS,
have sometimes been chosen as the primary end point,24,25
probably to avoid the confounding effects of poststudy treat-
ments. However, strictly speaking, it should be essential to
thoroughly investigate whether or how postrecurrent survival
is truly influenced by such therapies. Only one study to date
has shown that the median interval from the date of disease
progression to death increased by nearly 62% in the 1990s
over that in the 1980s,26 potentially indicating improved
salvage therapies in the later decade.
TTP and PFS have served as primary end points for
drug approval, but in TTP analysis, deaths before progression
are censored, and TTP would thus be less correlated with
OS.27 We here investigated the role of TTP because there
were limited number of trials presenting the PFS data. How-
ever, from such perspective, PFS would be a preferred reg-
ulatory end point compared with TTP. Thus, its role as a
surrogate marker for OS in advanced NSCLC should be
investigated in the future. Additionally, we could not obtain
full information about whether the schedule of disease as-
sessment was indeed the same in both treatment arms in each
TABLE 3. Degree of Associations between the MTTP Ratio and the MST Ratio in Various
Clinical Settings in the Simple Regression Analysis
No. of Trials Coefficient R2 p
Overalla 67 0.32 0.33 0.01
Various clinical settings with specific trial characteristicsa
Year of trial initiation
1998 and after 35 0.15 0.42 0.01
1997 and before 32 0.26 0.20 0.01
Old agents used
No 46 0.32 0.35 0.01
Yes 21 0.32 0.29 0.01
Cisplatin used
Yes 49 0.29 0.29 0.01
No 18 0.44 0.51 0.01
Carboplation used
Yes 23 0.36 0.47 0.01
No 44 0.30 0.28 0.01
Publication type
full text 51 0.29 0.31 0.01
abstract only 16 0.43 0.39 0.01
Description of sample size calculation
Yes 56 0.25 0.23 0.01
No 11 0.40 0.38 0.04
Description of definition for primary endpoint
Yes 55 0.37 0.36 0.01
No 12 0.14 0.16 0.20
Description of definition for TTP
Yes 37 0.27 0.35 0.01
No 30 0.45 0.34 0.01
Description of definition for OS
Yes 43 0.30 0.38 0.01
No 24 0.43 0.36 0.01
Description of definition both for OS and TTP
Yes 34 0.29 0.43 0.01
No 33 0.40 0.27 0.01
Sample size (No. of randomized pts)
500 27 0.32 0.22 0.01
250–499 20 0.38 0.38 0.01
249 20 0.22 0.27 0.02
The MST (median survival time) ratio in each trial was defined as the ratio of MST in the investigational arm to MST in
the reference arm. The MTTP ratio was defined similarly. All analyses were weighted by trial size.
aSubdivided using the median year as a cutoff value.
Pts, patients; R2, the proportion of variation; OS, overall survival; MTTP, median time to progression; MST, median survival
time; TTP, time to progression.
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trial. There were also many trials that lacked information
about TTP (Figure 1). Even when such information was
provided, the hazard ratios for OS and TTP were provided
infrequently (in only 8 of the 67 trials), leading us to use the
MST and MTTP ratios instead of these formal parameters.
One can thus argue that predictions based on these measures
may not be representative. We conducted all analyses using
abstracted data, but without individual patient data, and thus
could not perform patient-based data checking and/or reana-
lyze the association between TTP and OS. All of these issues
could have potentially confounded or biased our main results.
Another potential pitfall of TTP is that it has a tendency to be
clustered not as a continuous variable but around the times
that response is assessed. This issue, along with the limitation
of defining progression variably over the 15 years and more
than 50 trials, should be also explicitly noted.
The role of radiologic response as a surrogate marker
has been extensively investigated in the first-line chemother-
apy for advanced NSCLC. Progressive disease rate at week 8
is a powerful predictor of subsequent survival and provides
an early assessment of subsequent outcome from the data of
984 NSCLC patients entered onto 3 randomized Southwest
Oncology Group trials of platinum-based chemotherapy.28 In
another study using 320 patients with advanced NSCLC who
received four or more courses of first-line platinum-based
chemotherapy and attained partial response or stable disease,
those who only have stable disease after two cycles of
first-line chemotherapy have poorer survival outcome than
those in partial response.29 In contrast, Johnson et al.13
reported a modest association between the response rate and
survival. These discordant results would arise from the meth-
odological difference and different parameters used for their
analysis.
Considerable attention has been paid to the field of
surrogate markers, with some conflict as to the most appro-
priate definition of an adequate surrogate. The most widely
cited criteria are proposed by Prentice30 who stated that for a
surrogate marker to be valid, it must be correlated with the
true end point, and it must fully capture the net effect of the
treatment on the true end point. Furthermore, as discussed by
Fleming and DeMets,31 correlation of a surrogate with the
clinical outcome of interest is not solely sufficient to establish
the validity of a surrogate end point; proper validation re-
quires an understanding of the causal pathways of the disease
process and the mechanism of action of the treatment of
interest. Thus, we should further investigate the role of
surrogate markers in the treatment of NSCLC, taking such
issues fully into consideration.
In conclusion, our findings indicate that TTP in our
collection of relevant trials is too weakly correlated with
survival to use as a surrogate for survival in first-line chemo-
therapy for advanced NSCLC. With the increasing number of
active compounds available for the treatment of NSCLC,
even in second-line or later settings, the role of surrogate
markers, including TTP, should be investigated extensively.
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